These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan. Schreiber AR; Andress M; Diamond JR Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524 [No Abstract] [Full Text] [Related]
7. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis. Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142 [TBL] [Abstract][Full Text] [Related]
8. Current and emerging biologic therapies for triple negative breast cancer. Shaikh SS; Emens LA Expert Opin Biol Ther; 2022 May; 22(5):591-602. PubMed ID: 32713217 [TBL] [Abstract][Full Text] [Related]
9. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624 [TBL] [Abstract][Full Text] [Related]
10. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. Cipriano É; Mesquita A Breast Cancer (Auckl); 2021; 15():11782234211002491. PubMed ID: 33814914 [TBL] [Abstract][Full Text] [Related]
11. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Furlanetto J; Marmé F; Loibl S Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628 [TBL] [Abstract][Full Text] [Related]
12. Trop-2 as a Therapeutic Target in Breast Cancer. Sakach E; Sacks R; Kalinsky K Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497418 [TBL] [Abstract][Full Text] [Related]
13. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies. Kanwal B Cureus; 2021 Jul; 13(7):e16636. PubMed ID: 34458041 [TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Kagihara JA; Andress M; Diamond JR Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733 [TBL] [Abstract][Full Text] [Related]
15. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates]. Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340 [TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions. Morrison L; Okines A Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568617 [TBL] [Abstract][Full Text] [Related]
18. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278 [TBL] [Abstract][Full Text] [Related]
19. Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer. Fleming PJ; Karpio S; Lombardo N J Adv Pract Oncol; 2021 Sep; 12(7):747-752. PubMed ID: 34671504 [TBL] [Abstract][Full Text] [Related]
20. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher? Zardavas D Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]